Segurança da Ventilação na Cirurgia do Ombro em Cadeira de Praia: SafeLM Versus I-gel (SAFE-BCP)
Comparação da Máscara Laríngea Video SafeLM™ e da I-gel® para Segurança da Ventilação Após Transição para a Posição de Cadeira de Praia em Doentes Submetidos a Cirurgia do Ombro: Um Estudo Prospectivo Randomizado Controlado
This study aims to compare the performance of SafeLM™ video laryngeal mask airway and i-gel® supraglottic airway device in patients undergoing shoulder surgery in the beach chair position under general anesthesia. The primary objective is to evaluate oropharyngeal leak pressure (OLP) within the first 10 minutes after transition to the beach chair position. Secondary objectives include assessment of ventilation safety, need for airway interventions, and postoperative airway-related complications. This prospective randomized study will provide data on the effectiveness and safety of a video-guided supraglottic airway device compared to a conventional device in a clinically challenging position.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Shoulder surgery is frequently performed in the beach chair position (BCP), which may alter upper airway anatomy and increase the risk of airway-related complications. Changes in head and neck alignment, limited access to the airway due to surgical draping, and fluid extravasation during arthroscopy may negatively affect ventilation.
Supraglottic airway devices (SADs) are widely used in general anesthesia due to their ease of insertion and reduced invasiveness compared to endotracheal intubation. The i-gel® is a commonly used second-generation SAD with a non-inflatable cuff, while SafeLM™ is a video-guided laryngeal mask airway that allows real-time visualization of the glottic structures.
This prospective, randomized controlled study aims to compare SafeLM™ and i-gel® in patients undergoing shoulder surgery in the beach chair position. Patients aged 18-80 years with ASA physical status I-III will be randomly assigned to either the SafeLM™ or i-gel® group.
All patients will receive standardized anesthesia management, including induction with propofol and fentanyl and maintenance with sevoflurane. No neuromuscular blocking agents will be used. Following successful placement of the airway device, correct positioning will be confirmed by clinical and capnographic parameters.
The primary outcome of the study is the comparison of oropharyngeal leak pressure (OLP) within the first 10 minutes after transition to the beach chair position. OLP will be measured using a standardized technique with the adjustable pressure-limiting valve set to a maximum of 40 cmH2O.
Secondary outcomes include the incidence of ventilation impairment, need for airway interventions (such as jaw thrust, head repositioning, device adjustment or replacement), desaturation and hypercapnia episodes, first-attempt success rate, insertion time, and postoperative complications including sore throat, dysphonia, and postoperative nausea and vomiting.
In the SafeLM™ group, glottic visualization will be assessed using a standardized scoring system, and changes in glottic view associated with positional changes will be recorded.
This study aims to provide evidence on whether a video-guided supraglottic airway device offers advantages over a conventional device in maintaining airway stability and ventilation safety in the beach chair position.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ankara
-
Ankara, Ankara, Turquia (Türkiye), 06800
- Ankara Bilkent City Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients aged 18-80 years
- American Society of Anesthesiologists (ASA) physical status I-III
- Scheduled for elective shoulder surgery
- Body mass index (BMI) between 18-40 kg/m^2
- Adequate preoperative fasting (approximately 8 hours)
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Age <18 or >80 years
- Refusal to participate
- ASA physical status >= IV
- BMI >40 kg/m^2
- Failure of supraglottic airway device placement after three attempts
- Revision surgery
- Multiple trauma
- Maxillofacial fracture
- Active malignancy receiving radiotherapy or chemotherapy
- Active infection or ongoing antibiotic therapy (except prophylaxis)
- Chronic steroid or immunosuppressive therapy
- Full stomach
- Gastroesophageal reflux disease
- History of gastric surgery
- Gastroparesis
- Known egg allergy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: SafeLM Group
Participants randomized to this arm will receive airway management using the SafeLM™ video laryngeal mask airway during general anesthesia for shoulder surgery in the beach chair position. |
A video-guided supraglottic airway device used for airway management during general anesthesia in patients undergoing shoulder surgery in the beach chair position. It allows real-time visualization of glottic structures during placement. |
|
Comparador Ativo: i-gel Group
Participants randomized to this arm will receive airway management using the i-gel® supraglottic airway device during general anesthesia for shoulder surgery in the beach chair position. |
A second-generation supraglottic airway device used for airway management during general anesthesia in patients undergoing shoulder surgery in the beach chair position. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Oropharyngeal leak pressure (OLP) at two predefined time points: immediately after airway device placement in the supine position and 5 minutes after transition to the beach chair position
Prazo: Immediately after airway device placement in the supine position and 5 minutes after transition to the beach chair position during surgery
|
Comparison of oropharyngeal leak pressure (OLP) values measured immediately after insertion of the supraglottic airway device in the supine position and 5 minutes after transition to the beach chair position, as an indicator of airway sealing performance and ventilation safety. |
Immediately after airway device placement in the supine position and 5 minutes after transition to the beach chair position during surgery
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
First-attempt success rate of supraglottic airway device placement
Prazo: Immediately after airway device placement during surgery
|
Successful placement of the supraglottic airway device on the first insertion attempt. |
Immediately after airway device placement during surgery
|
|
Number of attempts required for supraglottic airway device placement
Prazo: Immediately after airway device placement during surgery
|
Total number of insertion attempts required to achieve successful placement of the supraglottic airway device. |
Immediately after airway device placement during surgery
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Ventilation safety and ventilation impairment events
Prazo: From airway device insertion until the end of surgery
|
Evaluation of ventilation safety based on the occurrence of ventilation impairment defined as SpO2 <94%, ETCO2 ≥50 mmHg, increased peak airway pressure with decreased tidal volume or air leak, and need for airway interventions. |
From airway device insertion until the end of surgery
|
|
Airway trauma and blood staining on device
Prazo: Immediately after device removal at the end of surgery
|
Presence of visible blood or signs of airway trauma on the supraglottic airway device after removal. |
Immediately after device removal at the end of surgery
|
|
Postoperative sore throat (VAS score) at early and late postoperative periods
Prazo: Continuously during the first 2 hours in the PACU and at 24 hours postoperatively in the ward
|
Severity of postoperative sore throat assessed using a visual analog scale (VAS) continuously during the first 2 hours in the post-anesthesia care unit (PACU) and reassessed at 24 hours postoperatively in the ward. |
Continuously during the first 2 hours in the PACU and at 24 hours postoperatively in the ward
|
|
Mean arterial pressure
Prazo: In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and during a stable intraoperative period (approximately 30-40 minutes after positioning)
|
Mean arterial pressure recorded in the supine position before transition and at predefined time points after transition to the beach chair position (1, 5, and 10 minutes), as well as during a stable intraoperative period (approximately 30-40 minutes after positioning). |
In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and during a stable intraoperative period (approximately 30-40 minutes after positioning)
|
|
Peak airway pressure (Ppeak)
Prazo: In the supine position before transition to the beach chair position, and at 1, 5, and 10 minutes after positioning, as well as during the stable intraoperative period
|
Peak airway pressure recorded in the supine position before transition to the beach chair position and at predefined time points after positioning (1, 5, and 10 minutes), as well as during the stable intraoperative period. |
In the supine position before transition to the beach chair position, and at 1, 5, and 10 minutes after positioning, as well as during the stable intraoperative period
|
|
Postoperative nausea and vomiting (PONV) incidence at early and late postoperative periods
Prazo: Continuously during the first 2 hours and at 24 hours postoperatively
|
Incidence of postoperative nausea and vomiting (PONV) continuously assessed during the first 2 hours in the post-anesthesia care unit (PACU) and evaluated again at 24 hours after surgery. |
Continuously during the first 2 hours and at 24 hours postoperatively
|
|
Oxygen saturation (SpO₂)
Prazo: In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and during a stable intraoperative period (approximately 30-40 minutes after positioning)
|
Peripheral oxygen saturation (SpO₂) recorded in the supine position before transition and at predefined time points after transition to the beach chair position (1, 5, and 10 minutes), as well as during a stable intraoperative period (approximately 30-40 minutes after positioning). |
In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and during a stable intraoperative period (approximately 30-40 minutes after positioning)
|
|
Heart rate
Prazo: In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and during a stable intraoperative period (approximately 30-40 minutes after positioning)
|
Heart rate recorded in the supine position before transition and at predefined time points after transition to the beach chair position (1, 5, and 10 minutes), as well as during a stable intraoperative period (approximately 30-40 minutes after positioning). |
In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and during a stable intraoperative period (approximately 30-40 minutes after positioning)
|
|
Tidal volume
Prazo: In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and at approximately 30-40 minutes after positioning during surgery
|
Tidal volume recorded in the supine position before transition and at predefined time points after transition to the beach chair position (1, 5, and 10 minutes), as well as at approximately 30-40 minutes after positioning during surgery. |
In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and at approximately 30-40 minutes after positioning during surgery
|
|
End-tidal carbon dioxide (EtCO₂)
Prazo: In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and at approximately 30-40 minutes after positioning during surgery
|
End-tidal carbon dioxide (EtCO₂) values recorded in the supine position before transition and at predefined time points after transition to the beach chair position (1, 5, and 10 minutes), as well as at approximately 30-40 minutes after positioning during surgery. |
In the supine position before transition and at 1, 5, and 10 minutes after transition to the beach chair position, and at approximately 30-40 minutes after positioning during surgery
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2025-OMUZ-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .